ZIOPHARM Oncology (NASDAQ:ZIOP) Sees Strong Trading Volume

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) saw strong trading volume on Thursday . 7,198,527 shares were traded during mid-day trading, an increase of 297% from the previous session’s volume of 1,812,039 shares.The stock last traded at $5.60 and had previously closed at $5.13.

A number of equities research analysts have recently issued reports on the stock. BidaskClub cut shares of ZIOPHARM Oncology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 13th. Raymond James reaffirmed an “outperform” rating and issued a $6.50 price objective on shares of ZIOPHARM Oncology in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $5.50 price objective on shares of ZIOPHARM Oncology in a research note on Thursday, May 9th. Finally, Zacks Investment Research cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. ZIOPHARM Oncology has an average rating of “Buy” and an average price target of $6.05.

The firm has a market cap of $833.90 million, a PE ratio of -10.90 and a beta of 2.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.33 and a current ratio of 6.33. The company’s 50-day simple moving average is $5.74 and its two-hundred day simple moving average is $4.49.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01). During the same quarter last year, the firm earned ($0.12) EPS. On average, analysts expect that ZIOPHARM Oncology Inc. will post -0.33 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Perceptive Advisors LLC bought a new stake in ZIOPHARM Oncology during the 2nd quarter valued at about $528,000. Royal Bank of Canada increased its stake in ZIOPHARM Oncology by 36.6% during the 2nd quarter. Royal Bank of Canada now owns 31,125 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 8,340 shares in the last quarter. United Services Automobile Association increased its stake in ZIOPHARM Oncology by 17.1% during the 2nd quarter. United Services Automobile Association now owns 22,182 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 3,246 shares in the last quarter. Voloridge Investment Management LLC bought a new stake in ZIOPHARM Oncology during the 2nd quarter valued at about $386,000. Finally, Nuveen Asset Management LLC bought a new stake in ZIOPHARM Oncology during the 2nd quarter valued at about $4,051,000. 40.67% of the stock is owned by institutional investors and hedge funds.

About ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Recommended Story: How is a Moving Average Calculated?

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.